1.
Introduction Radium-223 dichloride (radium-223), a first-in-class alphaemitting radiopharmaceutical [1] [2] [3] , has demonstrated survival benefits for patients with symptomatic bone metastases from castration-resistant prostate cancer (CRPC). In the randomized phase 3 ALSYMPCA study, radium-223 plus best standard of care (BSoC) versus placebo plus BSoC prolonged median overall survival (OS) by 3.6 mo (hazard ratio [HR] = 0.70; 95% confidence interval [CI]: 0.58-0.83; p < 0.001; median 14.9 mo vs 11.3 mo, respectively) and prolonged median time to first symptomatic skeletal event (SSE) by 5.8 mo (HR = 0.66; 95% CI: 0.52-0.83; p < 0.001; median 15.6 mo vs 9.8 mo, respectively) in patients with CRPC and symptomatic bone metastases [4, 5] . Additionally, radium-223 had a favorable safety profile with a low myelosuppression rate [4] . ALSYMPCA results led to radium-223 approval for the treatment of CRPC patients with symptomatic bone metastases and no known visceral metastatic disease [6] .
Unlike the phase 2 radium-223 dose-response pain study [7] , ALSYMPCA was not designed to evaluate the effect of radium-223 on pain; the primary endpoint was OS, and all patients received BSoC during the study, including treatments to manage pain (eg, external beam radiation therapy [EBRT], analgesics) [4] . ALSYMPCA eligibility required having symptomatic disease, broadly defined to include patients with regular use of analgesic medication (nonopioid or opioid) or pain-free patients who received EBRT for cancer-related bone pain in the 12 wk before randomization [4] . At baseline, 44% of radium-223 and 45% of placebo patients had no pain or had mild pain effectively managed without need for opioids; the remaining patients (56% radium-223 and 55% placebo) required opioids at study entry [4] .
The efficacy and favorable safety of radium-223 was observed in the overall ALSYMPCA population that included patients both with and without baseline opioid use. The question arises of whether the radium-223 survival advantage depended on patients' baseline symptom severity. In other words, would patients with no or minimal symptoms benefit from radium-223 as much as those with symptoms? To address this question, we assessed the efficacy and safety of radium-223 versus placebo in ALSYMPCA patients who did not require opioid therapy at baseline (ie, minimally symptomatic disease) versus those receiving opioids at baseline (ie, symptomatic disease). Additional analyses assessed the impact of radium-223 on delaying the need for opioids or EBRT for bone pain management and the safety of concomitant EBRT.
2.
Patients and methods Table 1 ). The planned follow-up was 3 yr from first study-drug injection.
Review boards at all participating centers approved the study, and all patients provided written informed consent. The study was registered with ClinicalTrials.gov, number NCT00699751.
Procedures
Opioids were permitted prior to and during ALSYMPCA, but were not a requirement for study entry. Investigators were free to manage bone pain during the study by starting nonopioid analgesics, or adding EBRT or opioids to pre-existing nonopioid analgesics as recommended by the WHO guidelines [10] . EBRT could be administered at any time prior to randomization or within 12 wk prior to randomization to fulfill the eligibility requirement of symptomatic disease and was allowed during the study as part of BSoC. Time to first EBRT use for bone pain was documented as a component of the secondary endpoint time to first SSE.
Opioid subgroups and study assessments
This analysis was designed to assess radium-223 efficacy and safety in the subgroups of patients who had or had not received opioids at baseline. Two subgroups were defined: the nonopioid subgroup included patients with no pain and no analgesic use (WHO ladder pain score 0) or mild pain and no opioid use (WHO ladder pain score 1) at baseline; the opioid subgroup included patients with moderate pain and occasional opioid use (WHO ladder pain score 2) or severe pain and regular daily opioid use (WHO ladder pain score 3) at baseline.
Outcomes
Patient outcomes by baseline opioid use and treatment group were 
Results

Nonopioid and opioid subgroups
Of the 921 patients randomized in the ALSYMPCA ITT population, 408 (44%) had no pain and no analgesic use (WHO ladder pain score 0) or mild pain managed with nonopioid therapy (WHO ladder pain score 1) at baseline (nonopioid subgroup: radium-223, n = 269; placebo, n = 139), and 513 (56%) had moderate pain with occasional opioids (WHO ladder pain score 2) or severe pain with regular daily opioids (WHO ladder pain score 3) at baseline (opioid subgroup: radium-223, n = 345; placebo, n = 168; Fig. 1 Crossover patients e 26 in the intention-to-treat population 24 in the safety population radium-223 = radium-223 dichloride. a Eighteen patients who were not being treated were withdrawn from the study before the first injection of the study drug (13 from the radium-223 group and five from the placebo group); an additional two patients received no treatment and had missing dates of withdrawal. b One patient was randomly assigned to the placebo but received radium-223 at week 0; this patient is included as randomly assigned in the intention-to-treat population (placebo group) and is included in the radium-223 group for the safety population. c Patients who discontinued treatment but continued to participate through follow-up were not regarded as withdrawn from the study; the study was ongoing at the time of the database lock, so patient numbers might not sum to the total number treated. d Patients who withdrew before their 3-yr follow-up visit were regarded as having withdrawn early from the study; the study was ongoing at the time of the database lock, so patient numbers might not sum to the total number treated. e Patients in the placebo group who received treatment with radium-223 after the study was unblinded; these patients were not regarded as having discontinued treatment or withdrawn from the study.
were completely pain free, although they met the study inclusion criteria for symptomatic disease, having received EBRT in the 12 wk prior to randomization.
Patient demographics and baseline characteristics
Demographics and baseline characteristics were generally balanced between nonopioid and opioid subgroups and the overall ALSYMPCA ITT population (Table 1) . Compared with radium-223 patients who required opioids, those in the nonopioid subgroup appeared to have less advanced disease, suggested by a greater proportion with tALP values <220 U/l, lower median tALP and lactate dehydrogenase values, better performance status, and less extensive skeletal disease. Also, fewer had prior docetaxel therapy and EBRT for pain in the 12 wk prior to randomization. A similar trend was seen among placebo patients ( Table 1) . Irrespective of treatment allocation, the survival duration and time to first SSE were longer in minimally symptomatic (ie, WHO ladder pain score 0-1/without opioid use) than in more symptomatic patients (ie, WHO ladder pain score 2-3/ with opioid use).
Efficacy: survival
Radium-223 significantly prolonged OS, regardless of baseline opioid use. Consistent OS benefits were seen with radium-223 treatment versus placebo in nonopioid (HR = 0.70; 95% CI: 0.52-0.93; p = 0.013; median 16.4 mo vs 12.8 mo, respectively) and opioid (HR = 0.68; 95% CI: 0.54-0.86; p = 0.001; median 13.9 mo vs 10.4 mo, respectively) subgroups (Fig. 2, A and B) . The treatment by opioid subgroup interaction was not statistically significant (p = 0.985), indicating that there is no difference in treatment effect between the opioid and nonopioid subgroups for OS.
Efficacy: SSE and other main secondary efficacy endpoints
Radium-223 treatment significantly reduced the risk of SSEs compared with placebo, regardless of baseline opioid use (nonopioid subgroup: HR = 0.56, 95% CI: 0.39-0.82, p = 0.002; opioid subgroup: HR = 0.72, 95% CI: 0.53-0.98, p = 0.038; (Fig. 2 , C and D). Additionally, all main secondary efficacy endpoints were met, regardless of baseline opioid use ( Table 2) . Please cite this article in press as: Parker 3.5.
Safety
No clinically meaningful treatment differences in the incidence of hematologic or nonhematologic AEs were observed between nonopioid and opioid subgroups (Table 3) , despite the slightly higher AE incidence (all grades and Grade 3/4) in the opioid subgroup for radium-223 and placebo patients, which may reflect more advanced disease in these patients. Although rare, Grades 3/4 neutropenia and thrombocytopenia occurred more frequently in radium-223 patients versus placebo patients, regardless of opioid subgroup (nonopioid subgroup: neutropenia in 2% vs 1%, thrombocytopenia in 5% vs 1%; opioid subgroup: neutropenia in 2% vs 1%, thrombocytopenia in 7% vs 2%; Table 3 ).
Radium-223 with concomitant opioids or EBRT for bone pain management
As mentioned above, opioids and EBRT were permitted as part of BSoC for bone pain management. Time to first use of opioids for bone pain was assessed in patients not receiving baseline opioids (ie, nonopioid subgroup). During the study, opioids were required by 36% (96/269) of radium-223 patients versus 50% (70/139) of placebo patients who were not receiving opioids at baseline. Radium-223 significantly delayed time to first opioid use for bone pain versus placebo (HR = 0.62, 95% CI: 0.46-0.85, p = 0.002; median not estimable vs 6.9 mo, respectively; Fig. 2E ). During the study, 30% (186/614) of radium-223 patients and 34% (105/307) of placebo patients received EBRT for bone pain. Radium-223 significantly reduced the risk of needing EBRT for bone pain by 33% versus placebo (HR = 0.67, 95% CI: 0.53-0.85, p = 0.001; Supplementary Fig. 1 ). No differences were seen in the safety profile between patients who did and did not receive concomitant EBRT for bone pain during the study (Table 4) . Additionally, myelosuppression rates were low regardless of concomitant EBRT.
Discussion
In ALSYMPCA, patients were required to have symptomatic disease to be eligible for the study; however, symptomatic was broadly defined, in that opioid use was not required and patients were defined as minimally symptomatic if they had regular use of any analgesic medication or if they had received EBRT in the 12 wk before randomization. This opioid subgroup analysis was conducted to determine if the radium-223 survival advantage in the overall ALSYMPCA Unless otherwise noted, the p value is from the log-rank test stratified by tALP, current use of bisphosphonates, and prior use of docetaxel. c n value is the number of patients with a confirmed tALP response/the total number of patients with nonmissing tALP values. A 30% reduction was defined relative to the baseline value, and was confirmed by a second tALP value approximately 4 or more wk later. d p value is from a Cochran-Mantel-Haenszel test adjusted for the stratification factors tALP, current use of bisphosphonates, and prior use of docetaxel. e n value is the number of patients with an elevated baseline tALP that normalized on study/the total number of patients with an elevated baseline tALP. At study entry, 44% of radium-223 patients and 45% of placebo patients were minimally symptomatic, with no pain or mild pain and no opioid use; of these, 4% of radium-223 patients and 1% of placebo patients were completely pain free at study entry. Radium-223 versus placebo significantly prolonged OS, reduced risk of initial SSE, and improved biochemical markers with a favorable safety profile in ALSYMPCA patients, regardless of baseline opioid use. For both radium-223 and placebo patients, minimally symptomatic patients (ie, WHO ladder pain score 0-1/without opioid use) had longer OS than patients with more symptomatic disease (ie, WHO ladder pain score 2-3/with opioid use). Results from these opioid subgroup analyses showed that radium-223 is effective and well tolerated in both minimally symptomatic nonopioid patients (WHO ladder pain score 0-1) and those with more advanced symptomatic disease who required opioid therapy (WHO ladder pain score 2-3), suggesting that appropriate timing of radium-223 treatment should not be based on symptom severity.
During ALSYMPCA, radium-223 treatment significantly delayed time to first opioid use and reduced the risk of needing EBRT for bone pain. Importantly, ALSYMPCA was not designed to evaluate the effect of radium-223 on pain; any observed pain response or lack thereof should not be considered a reason to stop radium-223 treatment. In fact, 63% of ALSYMPCA patients in the radium-223 group were able to receive all six injections of radium-223 [4] , the recommended course stated in approved radium-223 labeling. It is worth noting that concomitant EBRT had no effect on AE incidence or severity; as part of BSoC, EBRT may be used as needed to manage pain in patients undergoing radium-223 therapy. Using radium-223 earlier in the disease course, when patients are minimally symptomatic, may optimize treatment outcome and allow sequencing or combination use with other life-prolonging therapies. Additionally, radium-223 treatment has been shown to reduce hospitalization costs versus placebo [11] . Exploratory analyses from an international expanded access program with radium-223 (n = 696; included CRPC patients with symptomatic or asymptomatic bone metastases) showed that low or no pain at baseline was prognostic for prolonged survival, and that radium-223 combined with abiraterone acetate and/or enzalutamide was generally well tolerated [12] [13] [14] . Randomized trials are ongoing to prospectively evaluate radium-223 combined with abiraterone acetate and enzalutamide in asymptomatic or mildly symptomatic metastatic CRPC patients (NCT02043678; NCT02034552).
Conclusions
Radium-223 compared with placebo improved OS and reduced the risk of initial SSE with a favorable safety profile in patients with CRPC and symptomatic bone metastases, regardless of baseline opioid use. These results show that radium-223 is effective and well tolerated in both minimally symptomatic nonopioid patients (WHO ladder pain score 0-1) and patients with more advanced symptomatic disease who required opioid therapy (WHO ladder  pain Author contributions: Christopher C. Parker had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. 
